By Simonelli Valeria; Leuzzi Giuseppe; Basile Giorgia; D'Errico Mariarosaria; Fortini Paola; Franchitto Annapaola; Parlanti Eleonora;…
By Turcano, Lorenzo; Visaggio, Daniela; Frangipani, Emanuela; Missineo, Antonino; Andreini, Matteo; Altamura, Sergio; Visca, Paolo; Bresciani, Alberto
From SLAS Discovery (2017), 22(7), 897-905. Language: English, Database: CAPLUS, DOI:10.1177/2472555216689283
Pseudomonas infections are common among hospitalized, immunocompromised, and chronic lung disease patients. These infections are recalcitrant to common antibacterial therapies due to inherent antibiotic resistance. To meet the need of new anti-Pseudomonas drugs, a sensitive, homogenous, and robust assay was developed with the aim of identifying inhibitors of acyl-CoA synthetases (ACSs) from Pseudomonas. Given the importance of fatty acids for in vivo nutrition of Pseudomonas, such inhibitors might have the potential to reduce the bacterial fitness during infection. The assay, based on a coupled reaction between the Pseudomonas spp. ACS and the firefly luciferase, allowed the identification of three classes of inhibitors by screening of a diverse compd. collection. These compds. were confirmed to reversibly bind ACS with potencies in the micromolar range. Two classes were found to compete with acyl-CoA, while the third one was competitive with fatty acid binding. Although these compds. inhibit the bacterial ACS in cell-free assays, they show modest or no effect on Pseudomonas growth in vitro.